Label Value
DOI 10.1007/s40261-016-0383-1
TITLE Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors
TYPE article
Service Status Date Last Checked
Scopus Yes 2017-01-11T14:29:06.655495+00:00
Web of Science Yes 2018-04-08T12:30:17.483793
Compendex No 2019-12-19T09:49:53.357776